rethinkPeptides Search
Menu
Study breakdown

Peptide Hydrogel PuraStat Accelerates Gut Wound Healing After Endoscopic Tumor Removal in Pigs

evidence
The takeaway

PuraStat synthetic peptide hydrogel improved re-epithelialization and reduced wound size by 33% after endoscopic resections in a randomized pig study, with no adverse events.

33% wound size reduction

PuraStat-treated endoscopic resection sites showed significantly smaller wounds at 8 days compared to saline controls in a randomized pig study (p=0.001)

What the researchers found

Across 84 lesions in 21 pigs, PuraStat-treated wounds showed significantly greater re-epithelialization-to-defect ratios versus controls (p = 0.03), particularly after EMR. Endoscopic measurements showed 33% mean wound size reduction in the PuraStat group (p = 0.001). Histopathological analysis of defect area reduction approached but did not reach significance (p = 0.055). No adverse events were observed. The effect was more pronounced in EMR-induced lesions than ESD-induced lesions.

Why it matters

Endoscopic resection of GI tumors is increasingly common, but post-procedural bleeding and poor wound healing remain significant complications, sometimes requiring repeat procedures or hospitalization. PuraStat is already CE-marked and used clinically for hemostasis during endoscopy. This study suggests an expanded role — not just stopping bleeding, but actively promoting wound healing — which could improve patient outcomes and reduce healthcare costs associated with post-procedural complications.

How the study worked

Prospective, randomized, evaluator-blinded preclinical study in 21 pigs. Each animal underwent 2 EMR and 2 ESD procedures in the esophagus and stomach (84 total lesions). Lesions were randomized to PuraStat or saline application. Healing was evaluated at 8 days via follow-up endoscopy, gross pathology, and histopathological analysis. Primary endpoint was re-epithelialization-to-defect ratio.

What this study cannot tell us

This is an animal study in healthy pig tissue, which may not represent healing dynamics in diseased human tissue (e.g., tissue with prior radiation or chronic inflammation). The 8-day follow-up is short and doesn't capture complete healing. Endoscopic wound measurements have an estimated ±10% error margin. The histopathological difference between groups approached but did not reach statistical significance (p=0.055). The study was not powered for clinical outcomes like bleeding rates or stricture formation.

How to read the evidence

This is a well-designed randomized, evaluator-blinded preclinical study in a relevant large animal model. While the porcine GI tract is considered a good model for human endoscopic procedures, translation to human clinical outcomes requires clinical trials.

When this study was published

Published in 2026, this study expands the evidence for PuraStat beyond its established hemostatic use, exploring a new wound-healing indication that is directly relevant to current endoscopic practice.

The bigger picture

Self-assembling peptide hydrogels represent a versatile class of biomaterials finding applications across medicine. PuraStat (based on RADA16 peptide) was originally developed for hemostasis, but its scaffold-like properties also create an environment conducive to cell migration and tissue repair. This dual functionality — stopping bleeding AND promoting healing — exemplifies how peptide-based biomaterials can provide multiple therapeutic benefits from a single application, a concept increasingly relevant in minimally invasive surgery.

Questions still open

  • Would PuraStat show the same wound-healing benefit in human patients with diseased tissue after tumor removal?
  • Does the accelerated re-epithelialization translate into fewer delayed bleeding events or strictures in clinical practice?
  • Why was the healing benefit more pronounced after EMR than ESD — is it related to wound depth?

Common questions

What is PuraStat and how does it work?
PuraStat is a synthetic peptide hydrogel made from self-assembling peptides (RADA16 sequence) that forms a transparent gel when it contacts body tissues. Originally developed to stop bleeding during endoscopic procedures, it creates a protective scaffold over wound surfaces that appears to promote cell migration and tissue healing. It is already approved and commercially available for hemostatic use in endoscopy.
Why is wound healing after endoscopic tumor removal important?
When doctors remove tumors from the esophagus or stomach using endoscopy, they leave an open wound that must heal. Poor healing can lead to delayed bleeding (which may require emergency treatment), stricture formation (narrowing), or perforation. Accelerating wound healing could prevent these complications, reduce hospital readmissions, and improve patient outcomes after these increasingly common procedures.

Read the original research

Potential role of a synthetic peptide hydrogel in accelerating mucosal defect healing: evidence from a porcine model.

Surgical endoscopy, 40(2), 1549-1558

Citation

Tachecí, Ilja; Šembera, Štěpán; Zimandlová, Dana; Morávková, Paula; Vejvalková, Kateřina Geisler; Radochová, Věra; Ryška, Aleš; Cyrany, Jiří. (2026). Potential role of a synthetic peptide hydrogel in accelerating mucosal defect healing: evidence from a porcine model.. Surgical endoscopy, 40(2), 1549-1558. https://doi.org/10.1007/s00464-025-12374-0